P21 activated kinase 2 promotes pancreatic cancer growth and metastasis Retraction in /10.3892/ol.2023.13949

Yao,Guo‑Wang; Bai,Jing‑Rui; Zhang,Da‑Peng

doi:10.3892/ol.2019.10040

P21 activated kinase 2 promotes pancreatic cancer growth and metastasis

Retraction in: /10.3892/ol.2023.13949

Authors:
- Guo‑Wang Yao
- Jing‑Rui Bai
- Da‑Peng Zhang
View Affiliations

Affiliations: Department of the 1st Hepato-Biliary-Pancreatic Surgery, Tianjin Nankai Hospital, Tianjin 300100, P.R. China
Published online on: February 14, 2019 https://doi.org/10.3892/ol.2019.10040
Pages: 3709-3718
Copyright: © Yao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer has an overall 5‑year survival rate of only 9%, due to its rapid metastasis and poor prognosis. To combat this disease, novel therapeutic targets and biomarkers are required. In this study, immunohistochemistry was used to detect the expression of P21 activated kinase 2 (PAK2) protein in the tissues of cancer and the paired adjacent normal tissues. The association between PAK2 and the clinicopathologic features of patients with pancreatic cancer was subsequently analyzed. The results indicated that PAK2 was overexpressed in the cancer tissues, which indicated high pTNM stage, poor tumor grade, lymph node metastasis and vascular invasion. In addition, the results demonstrated evidence of a close association between PAK2 expression and poor prognosis of patients with pancreatic cancer. The results also suggested that PAK2 may promote pancreatic cancer cell proliferation and migration in vitro through clone formation, MTT, wound healing and Transwell assays. The present study further identified that PAK2 could stimulate pancreatic cancer growth and metastasis in mice. Decreased expression of proliferation marker protein Ki‑67 and proliferating cell nuclear antigen in response to PAK2 knockdown further verified the role of PAK2 in promoting cell proliferation by western blot analysis. In addition, the expression levels of matrix metallopeptidase (MMP) 2 and MMP9 were decreased in PANC1 and BxPC3 cell lines transfected with PAK2‑short hairpin RNA as indicated in western blot analysis, suggesting a function of PAK2 in promoting cell invasion. Collectively, these findings revealed a critical role for PAK2 in the development of pancreatic cancer and may have important implications for the management of this disease.

View Figures

View References

1	Garrido-Laguna I and Hidalgo M: Pancreatic cancer: From state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 12:319–334. 2015. View Article : Google Scholar : PubMed/NCBI
2	Makohon-Moore A, Brosnan JA and Iacobuzio-Donahue CA: Pancreatic cancer genomics: Insights and opportunities for clinical translation. Genome Med. 5:262013. View Article : Google Scholar : PubMed/NCBI
3	Subramani R, Gangwani L, Nandy SB, Arumugam A, Chattopadhyay M and Lakshmanaswamy R: Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review). Int J Oncol. 47:1203–1210. 2015. View Article : Google Scholar : PubMed/NCBI
4	Kenner BJ, Go VLW, Chari ST, Goldberg AE and Rothschild LJ: early detection of pancreatic cancer: The role of industry in the development of biomarkers. Pancreas. 46:1238–1241. 2017. View Article : Google Scholar : PubMed/NCBI
5	Ko AH: Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 33:1779–1786. 2015. View Article : Google Scholar : PubMed/NCBI
6	Cicenas J, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A and Cicenas J: KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer. Cancers (Basel). 9(pii): E422017. View Article : Google Scholar : PubMed/NCBI
7	Hayashi H, Kohno T, Ueno H, Hiraoka N, Kondo S, Saito M, Shimada Y, Ichikawa H, Kato M, Shibata T, et al: Utility of assessing the number of mutated KRAS, CDKN2A, TP53, and SMAD4 genes using a targeted deep sequencing assay as a prognostic biomarker for pancreatic cancer. Pancreas. 46:335–340. 2017. View Article : Google Scholar : PubMed/NCBI
8	Pihlak R, Valle JW and McNamara MG: Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget. 8:73240–73257. 2017. View Article : Google Scholar : PubMed/NCBI
9	Berger AW, Seufferlein T and Kleger A: Cystic pancreatic tumors: Diagnostics and new biomarkers. Chirurg. 88:905–912. 2017.(In German). View Article : Google Scholar : PubMed/NCBI
10	Donahue TR and Dawson DW: Leveraging mechanisms governing pancreatic tumorigenesis to reduce pancreatic cancer mortality. Trends Endocrinol Metab. 27:770–781. 2016. View Article : Google Scholar : PubMed/NCBI
11	Rane CK and Minden A: P21 activated kinases: Structure, regulation, and functions. Small GTPases. 5(pii): e280032014. View Article : Google Scholar : PubMed/NCBI
12	Kreis P and Barnier JV: PAK signalling in neuronal physiology. Cell Signal. 21:384–393. 2009. View Article : Google Scholar : PubMed/NCBI
13	Gadepalli R, Kotla S, Heckle MR, Verma SK, Singh NK and Rao GN: Novel role for p21-activated kinase 2 in thrombin-induced monocyte migration. J Biol Chem. 288:30815–30831. 2013. View Article : Google Scholar : PubMed/NCBI
14	Li X, Wen W, Liu K, Zhu F, Malakhova M, Peng C, Li T, Kim HG, Ma W, Cho YY, et al: Phosphorylation of caspase-7 by p21-activated protein kinase (PAK) 2 inhibits chemotherapeutic drug-induced apoptosis of breast cancer cell lines. J Biol Chem. 286:22291–22299. 2011. View Article : Google Scholar : PubMed/NCBI
15	Kosoff RE, Aslan JE, Kostyak JC, Dulaimi E, Chow HY, Prudnikova TY, Radu M, Kunapuli SP, McCarty OJ and Chernoff J: Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization. Blood. 125:2995–3005. 2015. View Article : Google Scholar : PubMed/NCBI
16	O'Hagan KL, Choi J, Pryshchep O, Chernoff J and Phee H: Pak2 LINKS TCR signaling strength to the development of regulatory T cells and maintains peripheral tolerance. J Immunol. 195:1564–1577. 2015. View Article : Google Scholar : PubMed/NCBI
17	Shao Y, Qi Y, Huang Y, Liu Z, Ma Y, Guo X, Jiang S, Sun Z and Ruan Q: Human cytomegalovirus miR-US4-5p promotes apoptosis via downregulation of p21-activated kinase 2 in cultured cells. Mol Med Rep. 16:4171–4178. 2017. View Article : Google Scholar : PubMed/NCBI
18	Eron SJ, Raghupathi K and Hardy JA: Dual Site phosphorylation of caspase-7 by PAK2 blocks apoptotic activity by two distinct mechanisms. Structure. 25:27–39. 2017. View Article : Google Scholar : PubMed/NCBI
19	Flate E and Stalvey JR: Motility of select ovarian cancer cell lines: Effect of extra-cellular matrix proteins and the involvement of PAK2. Int J Oncol. 45:1401–1411. 2014. View Article : Google Scholar : PubMed/NCBI
20	Gao C, Ma T, Pang L and Xie R: Activation of P21-activated protein kinase 2 is an independent prognostic predictor for patients with gastric cancer. Diagn Pathol. 9:552014. View Article : Google Scholar : PubMed/NCBI
21	Park J, Kim JM, Park JK, Huang S, Kwak SY, Ryu KA, Kong G, Park J and Koo BS: Association of p21-activated kinase-1 activity with aggressive tumor behavior and poor prognosis of head and neck cancer. Head Neck. 37:953–963. 2015. View Article : Google Scholar : PubMed/NCBI
22	Hao S, Luo C, Abukiwan A, Wang G, He J, Huang L, Weber CE, Lv N, Xiao X, Eichmüller SB and He D: miR-137 inhibits proliferation of melanoma cells by targeting PAK2. Exp Dermatol. 24:947–952. 2015. View Article : Google Scholar : PubMed/NCBI
23	Deng WW, Wu L, Bu LL, Liu JF, Li YC, Ma SR, Yu GT, Mao L, Zhang WF and Sun ZJ: PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma. Am J Transl Res. 8:3387–3397. 2016.PubMed/NCBI
24	Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, Tam KF, Ngan HY, Chan QK, Chan DC, Chan KY and Cheung AN: Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: Effects on prognosis and cell invasion. Int J Cancer. 127:21–31. 2010. View Article : Google Scholar : PubMed/NCBI
25	Nuche-Berenguer B and Jensen RT: Gastrointestinal hormones/neurotransmitters and growth factors can activate P21 activated kinase 2 in pancreatic acinar cells by novel mechanisms. Biochim Biophys Acta. 1853:2371–2382. 2015. View Article : Google Scholar : PubMed/NCBI
26	Varshney P and Dey CS: P21-activated kinase 2 (PAK2) regulates glucose uptake and insulin sensitivity in neuronal cells. Mol Cell Endocrinol. 429:50–61. 2016. View Article : Google Scholar : PubMed/NCBI
27	Nuche-Berenguer B, Ramos-Álvarez I and Jensen RT: The p21-activated kinase, PAK2, is important in the activation of numerous pancreatic acinar cell signaling cascades and in the onset of early pancreatitis events. Biochim Biophys Acta. 1862:1122–1136. 2016. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Yan BX, Ma JX, Zhang J, Guo Y, Mueller MD, Remick SC and Yu JJ: Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin. Cell Death Dis. 5:e9952014. View Article : Google Scholar : PubMed/NCBI
30	Wu R, Abramson AL, Symons MH and Steinberg BM: Pak1 and Pak2 are activated in recurrent respiratory papillomas, contributing to one pathway of Rac1-mediated COX-2 expression. Int J Cancer. 127:2230–2237. 2010. View Article : Google Scholar : PubMed/NCBI
31	Coniglio SJ, Zavarella S and Symons MH: Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms. Mol Cell Biol. 28:4162–4172. 2008. View Article : Google Scholar : PubMed/NCBI
32	Bright MD, Garner AP and Ridley AJ: PAK1 and PAK2 have different roles in HGF-induced morphological responses. Cell Signal. 21:1738–1747. 2009. View Article : Google Scholar : PubMed/NCBI
33	Menges CW, Sementino E, Talarchek J, Xu J, Chernoff J, Peterson JR and Testa JR: Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol Cancer Res. 10:1178–1188. 2012. View Article : Google Scholar : PubMed/NCBI
34	Cheng TY, Yang YC, Wang HP, Tien YW, Shun CT, Huang HY, Hsiao M and Hua KT: Pyruvate kinase M2 promotes pancreatic ductal adenocarcinoma invasion and metastasis through phosphorylation and stabilization of PAK2 protein. Oncogene. 37:1730–1742. 2018. View Article : Google Scholar : PubMed/NCBI
35	Li T, Zhang J, Zhu F, Wen W, Zykova T, Li X, Liu K, Peng C, Ma W, Shi G, et al: P21-activated protein kinase (PAK2)-mediated c-Jun phosphorylation at 5 threonine sites promotes cell transformation. Carcinogenesis. 32:659–666. 2011. View Article : Google Scholar : PubMed/NCBI
36	Siu MK, Yeung MC, Zhang H, Kong DS, Ho JW, Ngan HY, Chan DC and Cheung AN: p21-Activated kinase-1 promotes aggressive phenotype, cell proliferation, and invasion in gestational trophoblastic disease. Am J Pathol. 176:3015–3022. 2010. View Article : Google Scholar : PubMed/NCBI